261 related articles for article (PubMed ID: 22277591)
1. Polypseudorotaxanes of pegylated α-cyclodextrin/polyamidoamine dendrimer conjugate with cyclodextrins as a sustained release system for DNA.
Motoyama K; Hayashida K; Higashi T; Arima H
Bioorg Med Chem; 2012 Feb; 20(4):1425-33. PubMed ID: 22277591
[TBL] [Abstract][Full Text] [Related]
2. Potential use of polypseudorotaxanes of pegylated polyamidoamine dendrimer with cyclodextrins as novel sustained release systems for DNA.
Motoyama K; Hayashida K; Arima H
Chem Pharm Bull (Tokyo); 2011; 59(4):476-9. PubMed ID: 21467677
[TBL] [Abstract][Full Text] [Related]
3. Potential use of gamma-cyclodextrin polypseudorotaxane hydrogels as an injectable sustained release system for insulin.
Abu Hashim II; Higashi T; Anno T; Motoyama K; Abd-ElGawad AE; El-Shabouri MH; Borg TM; Arima H
Int J Pharm; 2010 Jun; 392(1-2):83-91. PubMed ID: 20298768
[TBL] [Abstract][Full Text] [Related]
4. Potential use of folate-polyethylene glycol (PEG)-appended dendrimer (G3) conjugate with α-cyclodextrin as DNA carriers to tumor cells.
Arima H; Arizono M; Higashi T; Yoshimatsu A; Ikeda H; Motoyama K; Hattori K; Takeuchi T; Hirayama F; Uekama K
Cancer Gene Ther; 2012 May; 19(5):358-66. PubMed ID: 22402627
[TBL] [Abstract][Full Text] [Related]
5. Slow-release system of pegylated lysozyme utilizing formation of polypseudorotaxanes with cyclodextrins.
Higashi T; Hirayama F; Yamashita S; Misumi S; Arima H; Uekama K
Int J Pharm; 2009 Jun; 374(1-2):26-32. PubMed ID: 19446755
[TBL] [Abstract][Full Text] [Related]
6. Sugar-appended polyamidoamine dendrimer conjugates with cyclodextrins as cell-specific non-viral vectors.
Arima H; Motoyama K; Higashi T
Adv Drug Deliv Rev; 2013 Aug; 65(9):1204-14. PubMed ID: 23602906
[TBL] [Abstract][Full Text] [Related]
7. Cyclodextrin/poly(ethylene glycol) polypseudorotaxane hydrogels as a promising sustained-release system for lysozyme.
Higashi T; Tajima A; Motoyama K; Arima H
J Pharm Sci; 2012 Aug; 101(8):2891-9. PubMed ID: 22678818
[TBL] [Abstract][Full Text] [Related]
8. Polypseudorotaxanes of pegylated insulin with cyclodextrins: application to sustained release system.
Higashi T; Hirayama F; Arima H; Uekama K
Bioorg Med Chem Lett; 2007 Apr; 17(7):1871-4. PubMed ID: 17291751
[TBL] [Abstract][Full Text] [Related]
9. Design and evaluation of polypseudorotaxanes of pegylated insulin with cyclodextrins as sustained release system.
Higashi T; Hirayama F; Misumi S; Arima H; Uekama K
Biomaterials; 2008 Oct; 29(28):3866-71. PubMed ID: 18620750
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo gene transfer by an optimized alpha-cyclodextrin conjugate with polyamidoamine dendrimer.
Kihara F; Arima H; Tsutsumi T; Hirayama F; Uekama K
Bioconjug Chem; 2003; 14(2):342-50. PubMed ID: 12643744
[TBL] [Abstract][Full Text] [Related]
11. Possible enhancing mechanisms for gene transfer activity of glucuronylglucosyl-β-cyclodextrin/dendrimer conjugate.
Anno T; Higashi T; Motoyama K; Hirayama F; Uekama K; Arima H
Int J Pharm; 2012 Apr; 426(1-2):239-247. PubMed ID: 22306427
[TBL] [Abstract][Full Text] [Related]
12. Folate-PEG-appended dendrimer conjugate with α-cyclodextrin as a novel cancer cell-selective siRNA delivery carrier.
Arima H; Yoshimatsu A; Ikeda H; Ohyama A; Motoyama K; Higashi T; Tsuchiya A; Niidome T; Katayama Y; Hattori K; Takeuchi T
Mol Pharm; 2012 Sep; 9(9):2591-604. PubMed ID: 22873579
[TBL] [Abstract][Full Text] [Related]
13. Design and evaluation of polyamidoamine dendrimer conjugate with PEG, α-cyclodextrin and lactose as a novel hepatocyte-selective gene carrier in vitro and in vivo.
Hayashi Y; Higashi T; Motoyama K; Mori Y; Jono H; Ando Y; Arima H
J Drug Target; 2013 May; 21(5):487-96. PubMed ID: 23570609
[TBL] [Abstract][Full Text] [Related]
14. Preparation of polypseudorotaxanes composed of cyclodextrin and polymers in microspheres.
Shinohara K; Yamashita M; Uchida W; Okabe C; Oshima S; Sugino M; Egawa Y; Miki R; Hosoya O; Fujihara T; Ishimaru Y; Kishino T; Seki T; Juni K
Chem Pharm Bull (Tokyo); 2014; 62(10):962-6. PubMed ID: 25273055
[TBL] [Abstract][Full Text] [Related]
15. Potential use of glucuronylglucosyl-β-cyclodextrin/dendrimer conjugate (G2) as a DNA carrier in vitro and in vivo.
Anno T; Higashi T; Motoyama K; Hirayama F; Uekama K; Arima H
J Drug Target; 2012 Apr; 20(3):272-80. PubMed ID: 22201459
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo gene delivery mediated by Lactosylated dendrimer/alpha-cyclodextrin conjugates (G2) into hepatocytes.
Arima H; Yamashita S; Mori Y; Hayashi Y; Motoyama K; Hattori K; Takeuchi T; Jono H; Ando Y; Hirayama F; Uekama K
J Control Release; 2010 Aug; 146(1):106-17. PubMed ID: 20678990
[TBL] [Abstract][Full Text] [Related]
17. Polypseudorotaxane formation of randomly-pegylated insulin with cyclodextrins: slow release and resistance to enzymatic degradation.
Higashi T; Hirayama F; Misumi S; Motoyama K; Arima H; Uekama K
Chem Pharm Bull (Tokyo); 2009 May; 57(5):541-4. PubMed ID: 19420793
[TBL] [Abstract][Full Text] [Related]
18. Improvement of gene delivery mediated by mannosylated dendrimer/alpha-cyclodextrin conjugates.
Wada K; Arima H; Tsutsumi T; Chihara Y; Hattori K; Hirayama F; Uekama K
J Control Release; 2005 May; 104(2):397-413. PubMed ID: 15907588
[TBL] [Abstract][Full Text] [Related]
19. Design and Evaluation of the Highly Concentrated Human IgG Formulation Using Cyclodextrin Polypseudorotaxane Hydrogels.
Higashi T; Tajima A; Ohshita N; Hirotsu T; Abu Hashim II; Motoyama K; Koyama S; Iibuchi R; Mieda S; Handa K; Kimoto T; Arima H
AAPS PharmSciTech; 2015 Dec; 16(6):1290-8. PubMed ID: 25776984
[TBL] [Abstract][Full Text] [Related]
20. Potential use of polyamidoamine dendrimer/alpha-cyclodextrin conjugate (generation 3, G3) as a novel carrier for short hairpin RNA-expressing plasmid DNA.
Tsutsumi T; Hirayama F; Uekama K; Arima H
J Pharm Sci; 2008 Aug; 97(8):3022-34. PubMed ID: 17932986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
